Back in January 2008, we were tracking 394 “active” public biotech companies. (By “active”, we mean companies that are filing with the SEC and not in bankruptcy or in a major restructuring due financial distress.) As of January 2010, we have 295 – a loss of ~25%.
About 48% of the companies that are no longer “active” have been acquired and 52% have gone out of business, filed bankruptcy, or are no longer filing with the SEC. The 295 number includes the addition of 3 IPOs in 2009, and the addition of a few companies that came out of bankruptcy in 2009.